I just bought $FLGT because it’s trading below its cash value, has solid growth potential in the diagnostics space, and the total addressable market is expanding significantly. The company has no debt and is poised for growth with upcoming oncology and reproductive panels that could drive revenue higher.

I believe Fulgent Genetics is significantly undervalued at under $20, considering its cash holdings and revenue potential. With fair value estimates reaching $32 to $42, I see a great opportunity for gains as the market eventually recognizes its worth, despite some lingering concerns about profitability.